No. of patients
|
822
|
820
|
822
|
821
| |
Demographic features
| | | | | |
Age, y
|
57.0 (50.0–64.0)
|
60.0 (53.0–68.0)
|
62.0 (56.0–71.0)
|
68.0 (59.0–74.0)
|
< 0.001
|
Male sex, n (%)
|
613 (74.6)
|
551 (67.2)
|
491 (59.7)
|
443 (54.0)
|
< 0.001
|
Current cigarette smoking, n (%)
|
354 (43.1)
|
310 (37.8)
|
289 (35.2)
|
253 (30.8)
|
< 0.001
|
Current alcohol drinking, n (%)
|
302 (36.7)
|
288 (35.1)
|
227 (27.6)
|
192 (23.4)
|
< 0.001
|
Clinical features
| | | | | |
Time from onset to randomization, h
|
10.0 (5.00–24.0)
|
12.0 (5.0–24.0)
|
10.0 (4.0–24.0)
|
10.0 (4.0–24.0)
|
0.12
|
Admission systolic BP, mm Hg
|
161.3 (152.0–178.7)
|
163.3 (152.0–178.7)
|
161.3 (152.0–176.0)
|
162.0 (152.0–178.7)
|
0.63
|
Admission diastolic BP, mm Hg
|
98.7 (90.0–101.3)
|
98.7 (90.0–101.3)
|
98.7 (90.0–100.7)
|
94.7 (88.7–100.0)
|
< 0.001
|
Triglyceride, mmol/L
|
1.4 (1.0–2.0)
|
1.6 (1.0–2.3)
|
1.5 (1.0–2.3)
|
1.5 (1.0–2.2)
|
0.78
|
Total cholesterol, mmol/L
|
4.8 (4.2–5.5)
|
5.0 (4.3–5.7)
|
5.1 (4.3–5.7)
|
5.1 (4.4–5.8)
|
< 0.001
|
LDL-cholesterol, mmol/L
|
2.8 (2.2–3.4)
|
2.9 (2.3–3.5)
|
2.9 (2.3–3.5)
|
2.9 (2.3–3.6)
|
0.009
|
HDL-cholesterol, mmol/L
|
1.2 (1.0–1.5)
|
1.2 (1.0–1.5)
|
1.2 (1.0–1.5)
|
1.3 (1.0–1.6)
|
< 0.001
|
Fasting plasma glucose, mmol/L
|
5.8 (5.1–7.2)
|
5.8 (5.1–7.4)
|
5.8 (5.2–7.2)
|
5.8 (5.0–7.1)
|
0.68
|
Admission NIHSS score
|
4.0 (2.0–8.0)
|
4.0 (2.0–7.0)
|
4.0 (3.0–7.0)
|
5.0 (3.0–8.0)
|
0.01
|
High-sensitivity C-reactive protein, mg/L
|
1.7 (0.6–4.1)
|
1.8 (0.8–4.9)
|
1.9 (0.7–4.5)
|
2.3 (0.8–5.5)
|
0.38
|
Medical history, n (%)
| | | | | |
Hypertension
|
658 (80.0)
|
648 (79.0)
|
643 (78.2)
|
633 (77.1)
|
0.13
|
Hyperlipidemia
|
44 (5.4)
|
65 (7.9)
|
65 (7.9)
|
63 (7.7)
|
0.09
|
Diabetes mellitus
|
140 (17.0)
|
158 (19.3)
|
148 (18.0)
|
136 (16.6)
|
0.66
|
Coronary heart disease
|
58 ( 7.1)
|
66 ( 8.0)
|
97 (11.8)
|
117 (14.3)
|
< 0.001
|
Family history of stroke, n (%)
|
185 (22.5)
|
163 (19.9)
|
135 (16.4)
|
132 (16.1)
|
< 0.001
|
Medication use history, n (%)
| | | | | |
Antihypertensive medications
|
372 (45.3)
|
408 (49.8)
|
403 (49.0)
|
431 (52.5)
|
0.007
|
Lipid-lowering medications
|
17 (2.1)
|
29 (3.5)
|
34 (4.1)
|
32 (3.9)
|
0.03
|
Ischemic stroke subtype, n (%)
| | | | | |
Thrombotic
|
644 (78.4)
|
648 (79.0)
|
628 (76.4)
|
599 (73.0)
|
0.004
|
Embolic
|
18 (2.2)
|
38 (4.6)
|
35 (4.3)
|
65 (7.9)
|
< 0.001
|
Lacunar
|
160 (19.5)
|
134 (16.3)
|
159 (19.3)
|
157 (19.1)
|
0.75
|
Randomized treatment, n (%)
|
404 (49.1)
|
420 (51.2)
|
400 (48.7)
|
423 (51.5)
|
0.56
|
Galectin-3, ng/ml
|
7.5 (5.2–10.1)
|
8.5 (5.9–11.3)
|
8.6 (6.3–11.8)
|
9.8 (6.5–13.9)
|
< 0.001
|